Biomerica, Inc. (BMRA)

Over the past six months, Biomerica, Inc.'s stock has declined by -27.04%, with a recent drop of -22.41% in the last month and a beta of 2.67. Key events include the release of Q1 fiscal 2026 results showing decreased net sales but a small profit due to a tax credit, a marketing agreement with Henry Schein for the inFoods® IBS Test, expansion of CDMO services, the launch of an AI-backed inFoods® IBS Trigger Food Navigator, UAE approval for the Fortel® Kidney Test, fiscal year 2025 results showing improved operating loss, UAE approval for the Fortel® Ulcer Test, a CPT® PLA Code for the inFoods® IBS test, and the appointments of Scott Madel as Chief Commercial Officer and Eric B. Chin to the Board of Directors, as well as clinical study results for Biomerica's inFoods® IBS being published.

Specific demand seasonality for Biomerica, Inc.'s products is not explicitly detailed. However, there are indications of sustained demand and expansion of CDMO services to meet accelerating market demand, suggesting a generally increasing demand rather than pronounced seasonal fluctuations.

Biomerica, Inc. is a biomedical technology company focused on developing, manufacturing, and marketing medical diagnostic and therapeutic products within the Healthcare sector. Their product portfolio is designed for early detection and monitoring of chronic diseases, particularly gastrointestinal issues, food intolerances, and diabetes. Key products include the inFoods® IBS test, an AI-backed inFoods® IBS Trigger Food Navigator, the hp+detect H. Pylori diagnostic test, and the Fortel® Kidney Test. The company also offers CDMO services.

Biomerica, Inc. has a global presence with operations and market reach in Europe, North America, Asia, South America, and the Middle East. Historically, a majority of the company's revenue has been earned from Asia. Recent expansions include approvals in the UAE for home use tests.

Biomerica's brand reputation has been positively influenced by developments around its inFoods® IBS product, including its feature in Biotherapeutics Quarterly and the launch of an AI-backed inFoods® IBS Trigger Food Navigator. The approval of the Fortel® Kidney Test and Fortel® Ulcer Test for home use in the UAE has also expanded the company's market reach. However, declining revenue and profitability margins, along with the stock trading near its 52-week low, could impact investor confidence.

Biomerica, Inc.'s ownership is a mix of institutional, retail, and individual investors. Institutional ownership is relatively low, ranging from approximately 0.78% to 8.69%. Insider ownership is notably high, estimated between 69.12% and 90%, with Zackary Irani, the CEO, being the largest individual shareholder.